Compare Stocks: RAPT, PTCT, XENE, and CNTA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTA Centessa Pharmaceuticals	$40.50	$40.16	$12.74 ▼ $40.56	$6.27B	1.11	2.15 million shs	N/A
PTCT PTC Therapeutics	$68.01 -9.9%	$77.57	$43.17 ▼ $90.87	$5.64B	0.53	1.28 million shs	4.33 million shs
RAPT Rapt Therapeutics	$58.02	$57.90	$5.67 ▼ $58.02	$1.61B	0.49	4.25 million shs	N/A
XENE Xenon Pharmaceuticals	$62.67 -2.4%	$59.30	$30.00 ▼ $72.66	$6.06B	0.61	1.18 million shs	736,905 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTA Centessa Pharmaceuticals	0.00%	0.00%	0.00%	+2.35%	+144.57%
PTCT PTC Therapeutics	-9.94%	-11.47%	-16.40%	+4.39%	+33.51%
RAPT Rapt Therapeutics	0.00%	0.00%	0.00%	0.00%	+412.54%
XENE Xenon Pharmaceuticals	-2.37%	-4.20%	+3.93%	+11.65%	+103.67%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTA Centessa Pharmaceuticals	$40.50	$40.16	$12.74 ▼ $40.56	$6.27B	1.11	2.15 million shs	N/A
PTCT PTC Therapeutics	$68.01 -9.9%	$77.57	$43.17 ▼ $90.87	$5.64B	0.53	1.28 million shs	4.33 million shs
RAPT Rapt Therapeutics	$58.02	$57.90	$5.67 ▼ $58.02	$1.61B	0.49	4.25 million shs	N/A
XENE Xenon Pharmaceuticals	$62.67 -2.4%	$59.30	$30.00 ▼ $72.66	$6.06B	0.61	1.18 million shs	736,905 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTA Centessa Pharmaceuticals	0.00%	0.00%	0.00%	+2.35%	+144.57%
PTCT PTC Therapeutics	-9.94%	-11.47%	-16.40%	+4.39%	+33.51%
RAPT Rapt Therapeutics	0.00%	0.00%	0.00%	0.00%	+412.54%
XENE Xenon Pharmaceuticals	-2.37%	-4.20%	+3.93%	+11.65%	+103.67%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTA Centessa Pharmaceuticals	2.21	Hold	$41.33	2.06% Upside
PTCT PTC Therapeutics	2.79	Moderate Buy	$95.75	40.79% Upside
RAPT Rapt Therapeutics	2.15	Hold	$50.63	-12.75% Downside
XENE Xenon Pharmaceuticals	3.00	Buy	$77.20	23.18% Upside

Current Analyst Ratings Breakdown

Latest RAPT, PTCT, XENE, and CNTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/31/2026	PTCT PTC Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$93.00 ➝ $104.00
7/31/2026	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$93.00 ➝ $106.00
7/20/2026	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$95.00 ➝ $93.00
7/16/2026	PTCT PTC Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$124.00 ➝ $130.00
7/7/2026	PTCT PTC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$82.00 ➝ $85.00
7/7/2026	PTCT PTC Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/6/2026	XENE Xenon Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/9/2026	PTCT PTC Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$75.00 ➝ $108.00
5/27/2026	PTCT PTC Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$76.00 ➝ $85.00
5/27/2026	XENE Xenon Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$80.00 ➝ $82.00

(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	$3.92 per share	N/A
PTCT PTC Therapeutics	$1.73B	3.26	$8.78 per share	7.75	($2.56) per share	-26.57
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	$11.51 per share	N/A
XENE Xenon Pharmaceuticals	$7.50M	807.77	N/A	N/A	$7.53 per share	8.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTA Centessa Pharmaceuticals	-$197.53M	-$1.79	N/A	N/A	N/A	N/A	-60.37%	-44.17%	8/11/2026 (Estimated)
PTCT PTC Therapeutics	$682.64M	-$0.58	N/A	31.20	5.92	-3.80%	-362.45%	-1.37%	N/A
RAPT Rapt Therapeutics	-$129.87M	-$11.06	N/A	N/A	N/A	N/A	-61.81%	-54.73%	N/A
XENE Xenon Pharmaceuticals	-$345.91M	-$4.70	N/A	N/A	N/A	N/A	-49.23%	-46.42%	8/10/2026 (Estimated)

Latest RAPT, PTCT, XENE, and CNTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	CNTA Centessa Pharmaceuticals	-$0.40	N/A	N/A	N/A	N/A	N/A
8/10/2026	Q2 2026	XENE Xenon Pharmaceuticals	-$1.14	N/A	N/A	N/A	$1.67 million	N/A
7/30/2026	Q2 2026	PTCT PTC Therapeutics	$0.2363	$0.92	+$0.6837	$0.92	$298.63 million	$360.52 million
5/7/2026	Q1 2026	PTCT PTC Therapeutics	-$0.45	-$0.03	+$0.42	-$0.03	$217.42 million	$272.55 million
5/7/2026	Q1 2026	XENE Xenon Pharmaceuticals	-$1.17	-$1.17	N/A	-$1.17	$1.36 million	N/A
5/5/2026	Q1 2026	CNTA Centessa Pharmaceuticals	-$0.38	-$0.52	-$0.14	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTA Centessa Pharmaceuticals	0.23	9.53	9.53
PTCT PTC Therapeutics	N/A	2.44	2.36
RAPT Rapt Therapeutics	N/A	12.04	12.04
XENE Xenon Pharmaceuticals	N/A	27.79	27.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTA Centessa Pharmaceuticals	82.01%
PTCT PTC Therapeutics	N/A
RAPT Rapt Therapeutics	99.09%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
CNTA Centessa Pharmaceuticals	4.09%
PTCT PTC Therapeutics	5.50%
RAPT Rapt Therapeutics	2.36%
XENE Xenon Pharmaceuticals	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTA Centessa Pharmaceuticals	200	154.73 million	148.40 million	Optionable
PTCT PTC Therapeutics	1,410	82.95 million	78.39 million	Optionable
RAPT Rapt Therapeutics	80	27.71 million	27.06 million	Optionable
XENE Xenon Pharmaceuticals	210	96.67 million	93.85 million	Optionable

RAPT, PTCT, XENE, and CNTA Headlines

Recent News About These Companies

Xenon Pharmaceuticals (NASDAQ:XENE) Rating Increased to Sell at Wall Street Zen

August 1 at 1:12 AM | americanbankingnews.com

Xenon Pharmaceuticals (NASDAQ:XENE) Raised to Sell at Wall Street Zen

August 1 at 1:11 AM | marketbeat.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 31 at 4:11 PM | financialpost.comF

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 31 at 4:01 PM | globenewswire.com

Janus Henderson Group PLC Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE

July 31 at 5:38 AM | marketbeat.com

Renaissance Technologies LLC Takes $17.47 Million Position in Xenon Pharmaceuticals Inc. $XENE

July 31 at 5:00 AM | marketbeat.com

Xenon to Report Q2 2026 Financial Results on August 6, 2026

July 30 at 4:10 PM | financialpost.comF

Xenon to Report Q2 2026 Financial Results on August 6, 2026

July 30 at 4:01 PM | globenewswire.com

Stempoint Capital LP Sells 207,850 Shares of Xenon Pharmaceuticals Inc. $XENE

July 30 at 6:07 AM | marketbeat.com

26,186 Shares in Xenon Pharmaceuticals Inc. $XENE Acquired by SummitTX Capital L.P.

July 30 at 5:20 AM | marketbeat.com

Redmile Group LLC Purchases 128,792 Shares of Xenon Pharmaceuticals Inc. $XENE

July 29 at 5:52 AM | marketbeat.com

Xenon Pharmaceuticals Inc. $XENE Shares Acquired by ADAR1 Capital Management LLC

July 29 at 3:12 AM | marketbeat.com

Xenon Pharmaceuticals Inc. $XENE is Rock Springs Capital Management LP's 9th Largest Position

July 28, 2026 | marketbeat.com

Eversept Partners LP Lowers Holdings in Xenon Pharmaceuticals Inc. $XENE

July 28, 2026 | marketbeat.com

Xenon Pharmaceuticals Inc. $XENE Shares Purchased by Swiss National Bank

July 28, 2026 | marketbeat.com

64,563 Shares in Xenon Pharmaceuticals Inc. $XENE Purchased by Castleark Management LLC

July 28, 2026 | marketbeat.com

Orbimed Advisors LLC Acquires 612,771 Shares of Xenon Pharmaceuticals Inc. $XENE

July 27, 2026 | marketbeat.com

Octagon Capital Advisors LP Purchases Shares of 490,000 Xenon Pharmaceuticals Inc. $XENE

July 27, 2026 | marketbeat.com

Commodore Capital LP Trims Position in Xenon Pharmaceuticals Inc. $XENE

July 27, 2026 | marketbeat.com

Affinity Asset Advisors LLC Buys 425,000 Shares of Xenon Pharmaceuticals Inc. $XENE

July 25, 2026 | marketbeat.com

Siren L.L.C. Has $76.67 Million Stock Holdings in Xenon Pharmaceuticals Inc. $XENE

July 24, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RAPT, PTCT, XENE, and CNTA Company Descriptions

Centessa Pharmaceuticals NASDAQ:CNTA

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

PTC Therapeutics NASDAQ:PTCT

$68.01 -7.51 (-9.94%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$69.50 +1.49 (+2.19%)

As of 07/31/2026 07:34 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Rapt Therapeutics NASDAQ:RAPT

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Xenon Pharmaceuticals NASDAQ:XENE

$62.67 -1.52 (-2.37%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$62.68 +0.02 (+0.02%)

As of 07/31/2026 07:34 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RAPT, PTCT, XENE, and CNTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RAPT, PTCT, XENE, and CNTA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RAPT, PTCT, XENE, and CNTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RAPT, PTCT, XENE, and CNTA Company Descriptions

Centessa Pharmaceuticals NASDAQ:CNTA

PTC Therapeutics NASDAQ:PTCT

Rapt Therapeutics NASDAQ:RAPT

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RAPT, PTCT, XENE, and CNTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RAPT, PTCT, XENE, and CNTA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RAPT, PTCT, XENE, and CNTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RAPT, PTCT, XENE, and CNTA Company Descriptions

Centessa Pharmaceuticals NASDAQ:CNTA

PTC Therapeutics NASDAQ:PTCT

Rapt Therapeutics NASDAQ:RAPT

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools